Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month High – Time to Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price reached a new 52-week high on Tuesday . The company traded as high as $34.00 and last traded at $33.7360, with a volume of 16031 shares traded. The stock had previously closed at $32.79.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday. Finally, Canaccord Genuity Group began coverage on Pulse Biosciences in a research report on Thursday, June 4th. They issued a “buy” rating and a $32.00 price target on the stock. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.33.

Pulse Biosciences Trading Down 3.4%

The firm’s fifty day simple moving average is $27.27 and its 200 day simple moving average is $22.55. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -31.14 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.25 million. As a group, sell-side analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insiders Place Their Bets

In other Pulse Biosciences news, Director Robert W. Duggan purchased 660,233 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the completion of the purchase, the director directly owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Paul A. Laviolette purchased 15,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $19.69 per share, with a total value of $295,350.00. Following the completion of the acquisition, the chief executive officer directly owned 15,000 shares in the company, valued at $295,350. The trade was a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 74.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PLSE. Argo Wealth Advisory LLC acquired a new position in Pulse Biosciences in the fourth quarter valued at $387,000. Westside Investment Management Inc. increased its position in shares of Pulse Biosciences by 2.9% during the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock worth $911,000 after purchasing an additional 1,886 shares in the last quarter. Quotient Wealth Partners LLC acquired a new stake in shares of Pulse Biosciences during the fourth quarter worth about $218,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Pulse Biosciences in the 2nd quarter valued at about $158,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after purchasing an additional 1,372 shares during the period. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.